BNF:

Immune system and malignant disease

Status:

Do Not Prescribe (DNP), Red

Decision Date:

None

Comments

DO NOT PRESCRIBE (DNP): NICE TA239: Breast cancer (metastatic). Not recommended post-menopause in oestrogen dependent metastatic disease, or if disease returned/worsened after anti-oestrogens (decision date - January 2012)

DO NOT PRESCRIBE (DNP)⁶: NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen receptor positive breast cancer.  (Decision date -  February 2018)

RED:^1,2 hospital use only

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again